- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
Stock Monitor: Dare Bioscience Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV) (''BiondVax''). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BVXV as the Company's latest news hit the wire. On April 11, 2018, the Company declared that it has enrolled first subject in the United States in a Phase-2 clinical trial of the Company's universal flu vaccine candidate, M-001. Conducted under an FDA Investigational New Drug (IND), the trial marks M-001's clinical debut in the US. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Dare Bioscience, Inc. (NASDAQ: DARE), which also belongs to the Healthcare sector as the Company BiondVax Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, BiondVax Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
The trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
BiondVax to Conduct Pivotal Clinical Efficacy Phase-3 Trial of M-001
News report suggests that on January 24, 2018, BiondVax signed a letter-of-intent (LOI) with a European contract research organization (CRO) aimed at conducting the first pivotal, clinical efficacy, Phase-3 study there assessing M-001 prior to the 2018/2019 flu season. The LOI included a €200K upfront fee to cover startup expenses. In March 2018, BiondVax signed a Master Service Agreement (MSA) with CRO to conduct the Phase-3 trial of M-001. The trial is planned in Europe later in 2018 and is co-funded by the European Union's European Investment Bank (EIB). The trial will enroll 9,630 participants aged 50 years and older across four to six countries over a period of two flu seasons.
About NIAID-Sponsored Phase-2 Clinical Trial
The NIAID-sponsored Phase-2 clinical trial is a multicenter, randomized, placebo-controlled study to assess the safety, reactogenicity, and immunogenicity of two doses of M-001, followed by seasonal quadrivalent influenza vaccine. The trial is being conducted at three sites in the United States, which are part of the NIAID-funded network of Vaccine and Treatment Evaluation Units (VTEUs). A total of 120 participants aged 18 to 49 years will be randomly assigned to receive either two doses of M-001 or two doses of a placebo, with the doses spaced several weeks apart. A few months following the second injection, all participants will receive a currently marketed unadjuvanted quadrivalent seasonal influenza vaccine. Safety and immunogenicity will be assessed and compared between the groups receiving M-001 and placebo.
M-001, BiondVax's lead candidate, is comprised of nine epitopes common to influenza virus strains including both influenza Type A and B. In six completed clinical trials in Israel and Europe (two Phase-1/2 and four Phase-2), BiondVax's universal flu vaccine candidate has been shown to be safe, well-tolerated, and immunogenic to a broad range of influenza strains. The Company first looks to obtain regulatory approval for M-001 as a primer to a pandemic or seasonal vaccine, and after accumulating enough safety and efficacy from real world data, the product will be tested and approved as a universal standalone vaccine for any existing or future pandemic or seasonal flu.
About BiondVax Pharmaceuticals Ltd
Founded in 2003 and based in Ness Ziona, Israel, BiondVax is an innovative biopharmaceutical company developing a Universal Flu Vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
Stock Performance Snapshot
April 12, 2018 - At Thursday's closing bell, BiondVax Pharma's stock rose 3.34%, ending the trading session at $6.19.
Volume traded for the day: 31.41 thousand shares, which was above the 3-month average volume of 14.94 thousand shares.
Stock performance in the previous three-month period - up 8.79%; and year-to-date - up 15.49%
After yesterday's close, BiondVax Pharma's market cap was at $1.62 billion.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.8% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the ''Author'') and is fact checked and reviewed by a third-party research service company (the ''Reviewer'') represented by a credentialed financial analyst. For further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the ''Sponsor''), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.